ЛИТЕРАТУРА

1. NMPN Study Group. Guidelinesfor the diagnosis and treatment of eosinophilia. 2^ndversion, September 2012, www.nordicmpd.org.: 4.
2. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic symdromes. Immunol Allergy Clin North Am. 2007; 27(3); 389-413.
3. Cools J, DeAngelo DJ, Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FGFR1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13): 1201-1214.
4. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008; 119 (4): 199-206.
5. B.J. Bain. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica. 2010 May; 95 (5): 696-698.
6. A.D. Klion. Eosinophilic Myeloproliferative Disorders. ASH Education Book December 10, 2011 vol. 2011 no. 1 257-263.
7. V Havelange, J-B Demoulin. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with eosinophilia. Journal of Blood Medicine. 2013; 4: 111-121.
8. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007; 92 (9): 1173-1179.
9. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008; 22 (11): 1999-2010.
10. M David, N.C.P. Cross, S Burgstaller, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood January 1, 2007 vol. 109 no.1: 61-64.
11. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010 Apr; 41 (4): 461-476.
12. A Chase, C Bryant, J Score, and N.C.P. Cross. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica. 2013 January; 98 (1): 103-106.
13. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algoritms. Leukemia 2008; 22: 14-22.
14. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975 Jan; 54 (1):1-27.
15. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59: 673-689.
16. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54: 169-184.
17. Roufosse F, Cogan E, Goldman M. Hypereosinophilic syndromes. Orphanet J Rare Diseasese 2007; 2: 37 (12 pages).
18. Оксфордский центр доказательной медицины. Уровни доказательности (Май 2001). Разработали Боб Филипс К.Б., Дейв Сакетт, Доуг Баденох, Шарон Штраус, Брайен Хайнес, Мартин Давес в ноябре 1998.
19. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol. 2003; 122: 173-179.
20. Gotlieb J. Molecular classification and pathogenesis of eosinophilic disorders. 2005 update. Acta Haematol 114: 7-25.
21. И.С.Немченко, Н.Д.Хорошко, А.Г.Туркина с соавт. FIP1L1-PDGFRa-позитивное миелопролиферативное заболевание с гиперэозинофилией: клиническая характеристика и возможности патогенетической терапии. Тер. архив. 2005. №7, С 90-92.
22. Verstovsec S, Giles FJ, Quintas-Cardama A, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuc Res 2006; 30 (12): 1499-1505.
23. Tabouret E, Charbonnier A, Mozziconacci MJ, et al. Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuc Res 2011; 35 (1): 136.
24. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106 (9): 3206-3213.
25. Imagawa J, Harada Y, Yoshida T, et al. [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. Rinsho Ketsueki 2011; 52 (7): 546-550. Japanise. [with English abstract].
26. Muller AM, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1-16.
27. Fruehauf S, Fiehn C, Haas R, Doehner H, Hunstein W. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy. Acta Haematol 1993; 89 (2): 91-3.
28. Bockenstedt PL, Santinga JT, Bolling SF. Alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994 Mar; 45 (3): 248-51.
29. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114 (1) :26-40.
30. Zhou L, Fu W, Yuan Z, Hou J. Complete moleculare remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome. Leuc Res 2010 Nov; 34 (11): 306-307.
31. Gotlieb J. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86: 678-688.
32. Gleich GJ, Lieferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002; 359: 1577-1578.
33. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis is response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473-478.
34. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-3397.
35. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion-gene positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61-64.
36. Bochner BS, Gleich GJ. What targeting eosinophils has taught us about their role in disease. J Allergy Clin Immunol 2010; 126: 16-25.
37. Klion AD. How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736-3741.
38. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: Point of care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85: 158-164.
39. Straumann A. Idiopathic eosinophilic gastrointestinal diseases in adults. Best Practice Res. Clin Gastroenterol 2008; 22: 481-496.
40. Sakamoto K, Erdreich-Epstein A, deClerck Y, et al. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992; 14: 348-351.
41. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63: 761-767.
42. Jabbour E, Verstovsek S, Giles F, et al. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005; 104: 541-546.
43. Хорошко Н.Д., Мокеева Р.А., Туркина А.Г. с соавт. Идиопатический и симптоматический гиперэозинофильные синдромы (сравнительная характеристика на основе 14 наблюдений). Тер. архив. 1997. №7, С. 26-33.
44. Хорошко Н.Д., Мокеева Р.А., Сысоева Е.П. с соавт. Бластный криз в исходе миелопролиферативного варианта идиопатического гиперэозинофильного синдрома. Гематол. и трансфузиол. 2000. т.45, №2, С. 37-42.
45. Абдулкадыров К.М. Туркина А.Г., Хорошко Н.Д. Рекомендации по диагностике и терапии хронического миелолейкоза. 2013, Санкт-Петербург, Москва. 80 с.
46. Воробьев А.И. Абдулкадыров К.М., Хорошко Н.Д. Диагностика и терапия хронического миелолейкоза. 2011, Москва. 53 с.

Для продолжения работы требуется вход / регистрация

Читать в приложении

Диагностика и лечение миелопролиферативных заболеваний с эозинофилией и идиопатического гиперэозинофильного синдрома

ЛИТЕРАТУРА

Оглавление